EDAP TMS S.A. Announces European Association Of Urology Recommends HIFU For Treatment Of Localized Prostate Cancer

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LYON, France, April 24, 2014 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced that HIFU for the primary treatment and salvage therapy of localized prostate cancer are recommended by the European Urology Association in its 2014 Guidelines released in April at the EAU’s Annual Congress held in Stockholm.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC